Epi CanaryEpi Canary
  • Home
  • Feed
  • Synthesis
  • Assessments
  • Scopes
  • Reliability
  • Sources
Epi Canary — Epidemic IntelligenceEvidence-led epidemic intelligence. Source-attributed evidence.
Arcede logoMade by Arcede
← Scopes/
Antimicrobial ResistanceAmr
  • Overview
  • Synthesis
  • Assessments
  • Evidence

Public note

For situational awareness and research transparency. Not medical advice.

Amractive

Antimicrobial Resistance

Surveillance of emerging AMR phenotypes, carbapenem-resistant Enterobacterales spread, and novel resistance gene dissemination across healthcare settings.

Open assessments

2

Tracked assessments currently open in this scope.

Evidence items

98

Source-attributed evidence available to this scope.

Source feeds

4

Configured sources contributing data to this investigation.

Last activity

Apr 11, 2026

Most recent scope activity captured in the system.

Evidence quality mix

T022
T133
T225
T312
T46

01

Synthesis

The current analyst view of this scope, at increasing levels of depth.

Steady state. Monitoring carbapenem resistance spread.

Global AMR surveillance data from GLASS and national reference labs shows continued spread of carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii. Novel NDM variants have been reported in South Asia. The system tracks resistance gene dissemination across borders via genomic surveillance.

02

Assessments

Open assessments being tracked inside this scope, ordered for fast review.

NDM-producing Enterobacterales prevalence in European ICUs will exceed 5% in EARS-Net 2026 data.

Resistance Emergence·active·31%·Through Mar 1, 2027·9 linked items·Apr 8, 2026

03

Recent evidence

The most recent source-attributed evidence flowing into this investigation.

GenBank submission: novel NDM-42 variant identified in Klebsiella pneumoniae isolate from hospital outbreak in Mumbai, India. Confers resistance to all tested carbapenems.

Apr 8, 2026
T0·GenBank·1 linked assessment
Auto-taggedOutbreakMutationResistance